Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Marie Skłodowska-Curie Action · Running

dIscOverNET Developing Immune Strategies to Counter tumor-immune-micrOnVironmEntal Resistance in NeuroEndocrine Tumors.

Coordinator
Universiteit Antwerpen, Belgium
Runs
1 January 2027 to 31 December 2030
Status
Running
EU funding
€4.6m
Total cost
—
Partners
23 organisations in 8 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101311447

What the project is doing

In the project's own words, from its summary on CORDIS.

Despite significant investments of resources, policies, global partnerships and social and financial efforts in the fight against cancer, we are currently still unable to achieve long-term disease control for patients with neuroendocrine tumors (NET). Moreover, despite the emphasis of both Europe’s Beating Cancer Plan and the European Initiative on Rare Cancers on advancing research and innovation in rare tumors, only limited progress has been made in the field of NET over the last decade.

Particularly, the transformative waves of immunotherapy success across oncology have not yet reached NET. By bringing together experts in NET biology, pioneers in immuno-oncology research, clinicians from NET expert centers, patient advocates, and representatives of the public health sector, dIscOverNET will lead to outstanding interdisciplinary and intersectoral research. This dynamic and synergistic collaboration, will explore the potential of leveraging the immune system for the treatment of NETs, which might be able to induce durable anti-tumor responses and cure NETs.

Through a comprehensive, multidisciplinary training program aligned with European doctoral training principles, the dIscOverNET doctoral candidates will be equipped to take on leading roles in European industry, academia, or government.

Topics

Who is involved

OrganisationCityCountryRole
Universiteit AntwerpenAntwerpenBelgiumCoordinator
Immunewatch BVAntwerpenBelgiumAssociatedpartner
SciensanoElseneBelgiumAssociatedpartner
SGS Belgium N.V.AntwerpenBelgiumAssociatedpartner
Universitair Ziekenhuis AntwerpenEdegemBelgiumAssociatedpartner
myNeoGentBelgiumParticipant
European Molecular Biology LaboratoryHeidelbergGermanyParticipant
European Neuroendocrine Tumor Society e. V. (ENETS)BerlinGermanyAssociatedpartner
Fundacio Institut D'investigacio Biomedica De BellvitgeL'Hospitalet De LlobregatSpainAssociatedpartner
Universidad De CordobaCordobaSpainParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Orano Ds - Demantelement Et ServiceMassyFranceAssociatedpartner
Universite Lyon 1 Claude BernardVilleurbanne CedexFranceParticipant
Universite Paris CiteParisFranceAssociatedpartner
Universita Degli Studi Di Bari Aldo MoroBariItalyParticipant
Crown Bioscience Netherlands BVLeidenNetherlandsParticipant
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsParticipant
Erasmus Universiteit RotterdamRotterdamNetherlandsAssociatedpartner
Google Cloud Technology Solutions Netherlands BVUtrechtNetherlandsAssociatedpartner
Institute of Cancer Research: the Royal Cancer Hospital LbgLondonUnited KingdomParticipant
University of LondonLondonUnited KingdomAssociatedpartner
International Neuroendocrine Cancer Alliance Inc.Newton, BostonUnited StatesAssociatedpartner
Oncoassign CorporationNew CastleUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI